SERTAD3 and breast cancer: lncRNA HNF1A-AS1 silencing resulted in the reduction of proliferation and tamoxifen resistance of BC cells through the miR-363/SERTAD3 axis, together with the inactivation of the TGF-β/Smad pathway, as demonstrated by both in vitro and in vivo experiments [122].